Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The transition of fallopian tube epithelial (FTE) cells to cancer cells originated from the TP53 gene mutation. The clonal expansion of the TP53 mutated cells can progress to FTE carcinoma and high-grade serous tubo-ovarian cancer (HGSCs). Genomic analysis of cancer cells demonstrates the various types of genetic abnormalities, including single nucleotide variants, gene deletion, copy number alterations, and gene silencing, which influence downstream gene expression and pathways. Poor response and resistance to current chemotherapy provoke the development of novel effective therapies for tumor treatment.
Creative Biolabs provides a platform for fallopian tube carcinoma cancer organoids with different genotypes for disease modeling and application to CAR therapy development.
Fig.1 Fallopian tube carcinoma cancer organoids establishment and characterization. (Yucer, et al., 2021)
|
| Reported Abnormal Genes | ||||
| TP53 | BRCA1 | BRCA2 | Nf1 | RAD51 |
| PTEN | EMSY | CCNE1 | MYC | |
The cancer organoids are advanced and easily manipulate models for CAR-T in vitro anti-tumor efficacy evaluations. Creative Biolabs provides the following cancer antigen-related products that could be used in CAR-T construction and examination assays.
| Target Antigen | Target Description | CAR-T Products |
| MUC16 | MUC16, also named CA125, is overexpressed in ovarian cancer and is regarded as an attractive target for therapy. | Anti-MUC16 CAR-T |
| Product Description |
Creative Biolabs is committed to cancer study using multiple advanced technologies and methods, and we provide a system of cancer organoid models to accelerate targeted cell therapy development for solid tumors. Please contact us for further discussion.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
